Global Iron Deficiency Anaemia Treatment Market Report and Forecast 2023-2031

Market Report | 2023-04-11 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License $5999.00
- Five User License $7999.00
- Corporate License $9999.00

Report description:

Global Iron Deficiency Anaemia Treatment Market Report and Forecast 2023-2031
Global Iron Deficiency Anaemia Treatment Market Outlook
The global iron deficiency anaemia treatment market size was valued at USD 1.9 billion in 2022 and is projected to grow at a CAGR of 4.2% during the forecast period of 2023-2031 to reach a value of USD 2.75 billion by 2031. The market growth can be attributed to the increasing prevalence of iron deficiency anaemia and the rising awareness about the importance of iron for overall health.
Introduction to the Iron Deficiency Anaemia Treatment Market
Iron deficiency anaemia treatment refers to the medical care provided to individuals with a shortage of iron in their body, leading to a reduction in red blood cell production. The treatment options include iron supplementation, dietary changes, and in severe cases, blood transfusions. The increasing prevalence of iron deficiency anaemia, particularly among women and children, is driving the demand for its treatment. Other factors such as rising awareness about the importance of iron, increasing government initiatives, and the growing demand for innovative treatment options are also expected to drive market growth.
Advancements in technology have played a significant role in the growth of the iron deficiency anaemia treatment market. New formulations of iron supplements, such as slow-release capsules and liquid iron supplements, have improved the effectiveness of iron supplementation and reduced side effects. This has expanded the reach of iron deficiency anaemia treatment and helped to meet the growing demand for services.
The iron deficiency anaemia treatment market is expected to continue to grow in the coming years, as awareness of the importance of iron continues to increase, and new treatment options and technologies are developed to meet the needs of people with iron deficiency anaemia. However, there are still significant barriers to accessing iron deficiency anaemia treatment, particularly in low- and middle-income countries, where access to healthcare services is often limited. Efforts are underway to address these barriers and improve access to iron deficiency anaemia treatment globally.
Iron Deficiency Anaemia Epidemiology
According to the World Health Organization, approximately 1.62 billion people globally suffer from anaemia, with iron deficiency being the most common cause. Iron deficiency anaemia can affect people of all ages and genders, but it is more prevalent in women, particularly those who are pregnant or lactating, and in children. In developing countries, it is estimated that 50% of

pregnant women and 40% of preschool children are anaemic.
Efforts to improve access to iron deficiency anaemia treatment should consider the unique needs of different age and gender groups, as well as the underlying factors that contribute to iron deficiency anaemia, such as poor nutrition, inadequate dietary intake, and malabsorption disorders. By addressing these factors, we can work towards reducing the burden of iron deficiency anaemia and improving access to effective treatment for all individuals, regardless of age or gender.
Iron Deficiency Anaemia Treatment Market Segmentations
The market can be segmented based on drug type, route od administration, treatment channel, and region:

Market Breakup by Drug Type
-Ferrous Sulphate
-Ferrous Gluconate
-Ferrous Fumarate
-Ferric Hydroxide
-Sodium Ferric Gluconate
-Iron Carbohydrates
-Others
Market Breakup by Route of Administration
-Tablets
-Capsules
-Liquids
Market Breakup by Treatment Channel
-Public
-Private
Market Breakup by Region
-North America
?United States of America
?Canada
-Europe
?United Kingdom
?Germany
?France
?Italy
?Others
-Asia Pacific
?China
?Japan
?India
?ASEAN
?Australia
?Others
-Latin America
?Brazil
?Argentina
?Mexico
?Others
-Middle East and Africa
?Saudi Arabia

?United Arab Emirates
?Nigeria
?South Africa
?Others
?

Iron Deficiency Anaemia Treatment Market Analysis

The global iron deficiency anaemia treatment market is expected to experience significant growth over the forecast period, driven by factors such as the increasing prevalence of iron deficiency anaemia and the rising awareness about the importance of iron supplementation in preventing and treating the condition.

The North America region is currently the largest market for the global iron deficiency anaemia treatment, dominating the market with a significant share. The region's large market share is driven by factors such as a high prevalence of iron deficiency anaemia, a well-established healthcare infrastructure, and strong investment in research and development. In addition, the growing adoption of new formulations of iron supplements is further driving the growth of the market in North America.

Europe is also a significant market for iron deficiency anaemia treatment, with countries such as Germany, France, and the United Kingdom leading the way. The region's market growth is driven by factors such as a large population base, increasing prevalence of iron deficiency anaemia, and the availability of iron supplements over the counter.

The Asia Pacific region is another region that is experiencing significant growth in the iron deficiency anaemia treatment market. The region's market growth is driven by factors such as a large population base, increasing awareness about the condition, and the growing adoption of iron supplements. In addition, government initiatives to address iron deficiency anaemia are helping to drive the growth of the market in the region.

Key Players in the Global Iron Deficiency Anaemia Treatment Market

The report provides a detailed analysis of the key players involved in the iron deficiency anaemia treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:

-Amgen Inc.
-F. Hoffmann-La Roche Ltd
-Novartis A.G.
-Pfizer Inc.
-Janssen Pharmaceuticals, Inc.
-AMAG Pharmaceuticals
-Teva Pharmaceutical Industries Ltd.
-Zydus Lifesciences Ltd.
-Covis Group S.
-Apotex
-Akebia Therapeutics, Inc.
-American Regent, Inc.
-Bayer Ag
-Merck & Co.

Table of Contents:

1 Preface
  1.1 Objectives of the Study
  1.2 Key Assumptions
  1.3 Report Coverage - Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Iron Deficiency Anaemia Overview

4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Iron Deficiency Anaemia Treatment Market
8.1 Global Iron Deficiency Anaemia Treatment Market Overview
8.2 Global Iron Deficiency Anaemia Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Iron Deficiency Anaemia Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Iron Deficiency Anaemia Treatment Market Forecast Value (2023-2031)
8.3 Global Iron Deficiency Anaemia Treatment Market by Drug Type
8.3.1 Market Overview
8.3.1.1 Ferrous Sulphate
8.3.1.2 Ferrous Gluconate
8.3.1.3 Ferrous Fumarate
8.3.1.4 Ferric Hydroxide
8.3.1.5 Sodium Ferric Gluconate
8.3.1.6 Iron Carbohydrates
8.3.1.7 Others
8.4 Global Iron Deficiency Anaemia Treatment Market by Therapy
8.4.1 Market Overview
8.4.1.1 Oral Iron Therapy
8.4.1.1.1 Capsules

8.4.1.1.2 Liquids
8.4.1.2 Parenteral Iron Therapy
8.4.1.2.1 Red Blood Cell Transfusion
8.4.1.3 Others
8.5 Global Iron Deficiency Anaemia Treatment Market by Treatment Channel
8.5.1 Market Overview
8.5.1.1 Public
8.5.1.2 Private
8.6 Global Iron Deficiency Anaemia Treatment Market by Region
8.6.1 Market Overview
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Latin America
8.6.1.5 Middle East and Africa
9 North America Iron Deficiency Anaemia Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Iron Deficiency Anaemia Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Iron Deficiency Anaemia Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India

11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Iron Deficiency Anaemia Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Iron Deficiency Anaemia Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Iron Deficiency Anaemia Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter's Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Amgen Inc.
15.1.1 Company Overview

15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 F. Hoffmann-La Roche Ltd
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Novartis A.G.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Pfizer Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Janssen Pharmaceuticals, Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 AMAG Pharmaceuticals
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Teva Pharmaceutical Industries Ltd.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Zydus Lifesciences Ltd.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Covis Group S.

15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Apotex
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Akebia Therapeutics, Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 American Regent, Inc.
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
15.13 Bayer Ag
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.13.5 Certifications
15.14 Merck & Co.
15.14.1 Company Overview
15.14.2 Product Portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisitions
15.14.5 Certifications
16 Global Iron Deficiency Anaemia Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket

SCOTTS INTERNATIONAL

Global Iron Deficiency Anaemia Treatment Market Report and Forecast 2023-2031

Market Report | 2023-04-11 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- - Print this form
- - Complete the relevant blank fields and sign
- - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	$5999.00
	Five User License	$7999.00
	Corporate License	$9999.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	
		Date	2025-05-13
		Signature	